Company intelligence / Profile preview

Beijing Bio-Targeting Therapeutics Technology

Ownership: Private
Development stage: Other

Overview

Beijing Bio‑Targeting Therapeutics Technology develops recombinant human nsIL12-based oncolytic adenoviral therapies. Its lead candidate, BioTTT001, is being evaluated in a Phase Ib/II study for recurrent/progressive high-grade brain glioma to assess safety, tolerability, biodistribution, and preliminary efficacy. Another program has reached Phase II development targeting metastatic gastric carcinoma.

Therapeutic areas: Oncology
Modalities: Oncolytic viruses (specifically oncolytic adenovirus)Recombinant proteins (recombinant human nsIL12)
Industry: Biotech

Drug pipeline

1 asset

BioTTT001

Partnerships

VacV Biotherapeutics (UK) Ltd

Beyond the preview

Go deeper on Beijing Bio-Targeting Therapeutics Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Bio-Targeting Therapeutics Technology.